Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma

Fig. 5

BRF2 is a prognostic marker for overall patient survival in invasive breast carcinoma. Using the cBioPortal [26], we queried a subset of the Invasive Breast Cancer Data Set (TCGA, Firehose Legacy) [28, 34, 35] for BRF2 alterations, restricting our analysis to complete patient data sets which included mutations, CNA, and mRNA microarray expression data (960 patients). BRF2 is altered in 21% of the patients queried and the overall survival Kaplan-Meier estimate was determined (a) comparing overall patient survival status, by month, in patients with BRF2 alterations (red line) to those without alterations in BRF2 (blue line). The logrank test p-value was 9.332e-3 and highly statistically significant. BRF2 overall survival status was compared to (b) ERBB2 (HER2), (c) ESR1 (ER), and (d) PIK3CA, known oncogenes and biomarkers. ERBB2 (HER2) (b) is altered in 18% of the patients queried with a logrank test p-value of 0.122. ESR1 (ER) (c) is altered in 9% of the patients queried with a logrank test p-value of 0.447. PIK3CA (d) is altered in 38% of patients queried with a logrank test p-value of 0.793. The Breast Invasive Carcinoma Data set (TCGA, Firehose Legacy) analyzed is available at the cBioPortal (www.cbioportal.org). Queries of the cBioPortal were performed in September 2019, October 2019, November 2019, January 2020, February 2020, and March 2020

Back to article page
\